All In Biotech

Drug Trial Radar · NCT07885462

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills

Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills(MAID)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 496 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

496

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Qilu Hospital of Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety. Study Design: Randomized, double-blind, placebo-controlled, multicenter clinical trial. Study population: Patients with ischemia-related CMVD and myocardial infarction-related CMVD. Intervention:Treatment group:standard therapy plus CDDP, Twenty pills (27 mg each) orally, three times daily after meals.Control group:standard therapy plus matching placebo, Twenty pills (27 mg each) orally, three times daily after meals.Treatment duration 12 months. Primary Endpoint: Change in CFRmax from baseline to Month 12 (ΔCFRmax-12m) by Transthoracic Doppler echocardiography(TTE).

Conditions

  • Coronary Microvascular Disease

Interventions

  • Compound Danshen Dripping PillsDrug

    20 pills (540 mg) orally three times daily for 12 months. Each pill weighs 27 mg, containing Radix Salviae miltiorrhizae, Radix Notoginseng, and Borneolum Syntheticum. Manufactured and supplied by Tasly Pharmaceutical Group Co., Ltd.

  • PlaceboDrug

    Placebo pills identical to Compound Danshen Dripping Pills in appearance, taste, and packaging, 20 pills orally three times daily for 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending arteryTime frame: Baseline, 6 months, and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.